\
&
Contact us
\
&
Contact us
This was 9 months ago
LocationHybrid in Brussels and online
ProgrammesThe EDF Info Days 2025 will take place on 2-3 April in hybrid format in Brussels and online.
The European Commission invites you to an exclusive Information Day and Networking Event for the 2025 European Defence Fund (EDF) funding opportunities.
This year’s EDF Info Days will feature:
✅ A detailed presentation of the EDF 2025 calls for proposals by DG DEFIS experts
✅ Insights into the EDF proposal landscape, including submission process and funding opportunities
✅ Thematic pitch sessions to help you find partners, form R&D consortia and refine project proposals
✅ EU Defence Investor Day, connecting investors and entrepreneurs in the defence sector
✅ Matchmaking opportunities both on site and virtually before, during and after the event
Who should attend:
Potential applicants from public and private entities in EU Member States and Norway. More details on eligibility can be found on the EDF webpage.
Key Deadlines:
📌 Deadline to submit pitch presentations proposals: 28 February 2025
📌 Registration for participation: 14 March 2025
Don’t miss this opportunity to collaborate, innovate, and secure funding for your defence R&D projects. Register now to secure your spot and gain access to exclusive matchmaking services!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
